Fill | Survey of Clinician Perspectives on the Use of SBRT for Oligometastatic Breast Cancer
You are invited to participate in this survey on the use of stereotactic body radiotherapy (SBRT) in oligometastatic breast cancer. In the UK, SBRT is commissioned for the treatment of up to 3 metachronous oligometastatic sites of disease. Given variations in international practices, this survey aims to understand referral patterns and treatment approaches for SBRT in oligometastatic breast cancer with a view to informing future clinical trial design. This survey will take approximately 15 minutes to complete. Confidentiality Data collected for research purposes only, ensuring confidentiality of identifiable information. Access limited to researchers for 2 years, then securely destroyed in compliance with GDPR. Consent Submitting this online survey indicates your implied consent to participate. If you have any questions related to this study, please contact Dr Sukhdeep Nagpal (research fellow) email: sukhdeep.nagpal@icr.ac.uk